The FDA approved an expanded indication for Enbrel (etanercept) to inhibit the structural damage of active arthritis in patients with psoriatic arthritis, reported Amgen Inc. and Wyeth Pharmaceuticals.
Discovering Dermatology Times: March 2024 Enhancing Psoriasis Management Supplement
ReV Up Your Vitiligo Treatment Strategies
Skin Swab Analysis Reveals Early Predictors of Atopic Dermatitis in Infants
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
Reviewing Late-Breaking Research From AAD 2024
A Spotlight on SCIN: A New Tool From Google and Researchers at Stanford Medicine